[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]
Views 1,180
Citations 0
Correction
October 2017

Errors in Tables

JAMA Oncol. 2017;3(10):1431. doi:10.1001/jamaoncol.2017.2897

In the Review titled “Biosimilars in Oncology in the United States: A Review,”1 published online July 20, 2017, there were errors in Table 2 and Table 3. In Table 2, footnote “c” should have read “FDA-approved biosimilars; none are interchangeable; tbo-filgrastim was not approved under 351(k) Biosimilar Pathway.” Footnote “d” should have broken at the colon, and the remaining statement should have been a new footnote “e.” In addition, citation to footnote “d” was removed after “FDA approved” in column 1 and a new citation to footnote “e” was added to row 7 of column 2 after “ABP 215 (Amgen).” Finally, in Table 3, the “yes” designation in column 4, row 6 should have been “no.” This article was corrected online.

References
1.
Nabhan  C, Parsad  S, Mato  AR, Feinberg  BA.  Biosimilars in oncology in the United States: a review  [published online July 20, 2017].  JAMA Oncol. doi:10.1001/jamaoncol.2017.2004Google Scholar
×